N

NVS

Novartis

115.30

1.56+1.37%
After Hours: 115.00  -0.30  -0.26%18:51 08/01 EDT
1D
5D
Daily
Weekly
Monthly
Quarterly
Yearly
OPEN/PREV CLOSE112.40/113.74
TODAY RANGE112.34-115.54
VOL1.93M
MARKET CAP223.20B
52 WEEK RANGE92.62-124.83
AVG VOL (3M)1.63M
% TURNOVER0.10%
TURNOVER--
P/E (TTM)16.81
% RANGE2.78%
EPS(TTM)6.86
P/E(FORWARD)15.41
P/B5.32
BVPS21.69
DIVIDEND3.994
P/S4.403
BETA--
DIV YIELD3.46%
FREE FLOAT MKT CAP223.20B
SHARES OUTSTANDING1.94B
NEXT EARNINGS01/29-02/02
FREE FLOAT1.94B
LOT SIZE1
EX-DATE03/12/2025
News
Press Releases
Financial Reports
Profile
Same Industry
Name/Symbol
Change%
Price

N

Novartis

NVS

+1.37%
115.30

M

McKesson

MCK

+0.76%
698.80

B

Biogen Inc

BIIB

+3.09%
131.95

A

Amgen Inc

AMGN

+0.60%
296.88

B

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%
0.0301

S

Shire

SHPG

--
179.20

L

Lilly Eli & Co

LLY

+3.01%
762.33

C

Celgene

CELG

--
108.24

T

Therapeuticsmd Inc

TXMD

-0.89%
1.11

J

Johnson & Johnson

JNJ

+1.57%
167.33

A

Abbvie Inc

ABBV

+3.28%
195.22

Z

Zoetis Inc

ZTS

+1.09%
147.38

G

Gilead Sciences Inc

GILD

+0.79%
113.18

N

Novo-Nordisk A/S

NVO

+2.38%
48.19

B

Bristol-Myers Squibb Co

BMY

+2.12%
44.23

A

Alexion Pharms

ALXN

+1.70%
182.50

P

Pfizer

PFE

+0.86%
23.49

S

Sanofi FR

SNY

+2.43%
46.75

S

Sanofi FR

GCVRZ

0.00%
0.8711

D

Dr Reddys Labs

RDY

-1.97%
13.94

G

GSK PLC

GSK

+1.10%
37.56
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.